Adina Makover - Evogene Independent Director
| EVGN Stock | ILA 261.20 15.20 6.18% |
Director
Dr. Adina Makover as Independent Director at Evogene Ltd since February 2003. She is a member of the Compensation and Nominating committees. Dr. Makover work experience includes the following roles Director at GeneGrafts Ltd, Spine 21 Ltd, EarlySense Ltd, PerfAction Technologies Ltd, External Director at Kadimastem Ltd, Board Observer at Argo Medical Ltd and investment manager of Life Sciences ventures at ProSeed VC Fund Ltd since 2003.
| Age | 66 |
| Tenure | 21 years |
| Professional Marks | MBA |
| Phone | (972) 8 946 6724 |
| Web | www.evogene.com |
Evogene Management Efficiency
The company has return on total asset (ROA) of (0.2789) % which means that it has lost $0.2789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6255) %, meaning that it generated substantial loss on money invested by shareholders. Evogene's management efficiency ratios could be used to measure how well Evogene manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Arie Ovadia | Compugen | 67 | |
| Rachel Ari | Bonus Biogroup | 55 | |
| Joshua Shemer | Compugen | 63 | |
| Yair Aharonowitz | Compugen | 73 | |
| JeanPierre Bizzari | Compugen | 64 | |
| Yehuda Reznik | Bonus Biogroup | 68 | |
| Eran Perry | Compugen | N/A | |
| Gilead Halevy | Compugen | 51 | |
| Gil Shapira | Bonus Biogroup | 56 | |
| Michal Preminger | Compugen | N/A | |
| Daniel BenLulu | Bonus Biogroup | 54 | |
| Sanford Zweifach | Compugen | 60 | |
| Avi Slonim | Bonus Biogroup | 38 | |
| Dov Hershberg | Compugen | 74 | |
| Ruth Arnon | Compugen | 86 | |
| Kinneret Savitsky | Compugen | 50 | |
| Batia Avital | Bonus Biogroup | 54 | |
Management Performance
| Return On Equity | -0.63 | |||
| Return On Asset | -0.28 |
Evogene Leadership Team
Elected by the shareholders, the Evogene's board of directors comprises two types of representatives: Evogene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evogene. The board's role is to monitor Evogene's management team and ensure that shareholders' interests are well served. Evogene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evogene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Kapel, Executive Vice President-Technology | ||
| Assaf Oron, Executive VP Corporate Devel. | ||
| Martin Gerstel, Chairman of the Board | ||
| Oded Shoseyov, Director | ||
| Eyal Leibovitz, CFO | ||
| Yaron Eldad, Chief Officer | ||
| Eyal Ronen, Exec Devel | ||
| Adina Makover, Independent Director | ||
| Adrian Percy, Director | ||
| Sarit Firon, Independent Director | ||
| Sassi Masliah, Exec Devel | ||
| Yuval BenGalim, COO | ||
| Michael Anghel, External Director | ||
| Liat Wejgman, VP HR | ||
| Eran Kosover, Executive Vice President & General Manager Ag-Chemicals | ||
| Ofer CPA, CEO Pres | ||
| Ofer Haviv, President, Chief Executive Officer | ||
| Amos Shachar, Vice President of Project Management | ||
| Ido Dor, Executive Vice President & General Manager Ag-Biologicals | ||
| Sigal Fattal, Executive Officer | ||
| Dotan Borenstein, Chief Ltd | ||
| Nir Arbel, Chief Officer | ||
| Hagai Karchi, Chief Technology Officer & Head of R&D Ag-Biologicals | ||
| Leon Recanati, Independent Director | ||
| Alin SelaBrown, Vice President Screening & Validation Systems | ||
| Kinneret Savitsky, Independent Director | ||
| Eli Zangvil, Director | ||
| Eyal Emmanuel, Executive Vice President-R&D | ||
| Assaf Kacen, Chief Operation Officer | ||
| Arnon Heyman, Vice President & General Manager of Ag-Seeds | ||
| Kinneret Savitzky, External Director | ||
| Simcha Sadan, Director | ||
| Alex Taskar, Chief Financial Officer | ||
| Lea Bloom, Director of Administration & Human Resources | ||
| Ziv Kop, Independent Director | ||
| Elran MBA, Chief Ltd |
Evogene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evogene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | |||
| Return On Asset | -0.28 | |||
| Operating Margin | (24.02) % | |||
| Current Valuation | 8.8 M | |||
| Shares Outstanding | 41.22 M | |||
| Shares Owned By Insiders | 3.58 % | |||
| Shares Owned By Institutions | 3.37 % | |||
| Price To Book | 0.93 X | |||
| Price To Sales | 73.01 X | |||
| Revenue | 930 K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Evogene in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Evogene's short interest history, or implied volatility extrapolated from Evogene options trading.
Pair Trading with Evogene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.
The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Evogene Stock analysis
When running Evogene's price analysis, check to measure Evogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evogene is operating at the current time. Most of Evogene's value examination focuses on studying past and present price action to predict the probability of Evogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evogene's price. Additionally, you may evaluate how the addition of Evogene to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |